Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Christine Walsh to Adult

This is a "connection" page, showing publications Christine Walsh has written about Adult.

 
Connection Strength
 
 
 
0.237
 
  1. Cohen JG, Prendergast E, Geddings JE, Walts AE, Agadjanian H, Hisada Y, Karlan BY, Mackman N, Walsh CS. Evaluation of venous thrombosis and tissue factor in epithelial ovarian cancer. Gynecol Oncol. 2017 07; 146(1):146-152.
    View in: PubMed
    Score: 0.032
  2. Prendergast EN, Holzapfel M, Mueller JJ, Leitao MM, Gunderson CC, Moore KN, Erickson BK, Leath CA, Diaz Moore ES, Cohen JG, Walsh CS. Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma - A multi-institutional cohort. Gynecol Oncol. 2017 Feb; 144(2):274-278.
    View in: PubMed
    Score: 0.031
  3. Diaz ES, Walts AE, Karlan BY, Walsh CS. Venous thromboembolism during primary treatment of ovarian clear cell carcinoma is associated with decreased survival. Gynecol Oncol. 2013 Dec; 131(3):541-5.
    View in: PubMed
    Score: 0.025
  4. Fleming ND, Agadjanian H, Nassanian H, Miller CW, Orsulic S, Karlan BY, Walsh CS. Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer. Cancer. 2012 Feb 01; 118(3):689-97.
    View in: PubMed
    Score: 0.022
  5. Walsh CS, Blum A, Walts A, Alsabeh R, Tran H, Koeffler HP, Karlan BY. Lynch syndrome among gynecologic oncology patients meeting Bethesda guidelines for screening. Gynecol Oncol. 2010 Mar; 116(3):516-21.
    View in: PubMed
    Score: 0.019
  6. Walsh CS, Miller CW, Karlan BY, Koeffler HP. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. Gynecol Oncol. 2007 Mar; 104(3):660-4.
    View in: PubMed
    Score: 0.016
  7. Walsh C, Holschneider C, Hoang Y, Tieu K, Karlan B, Cass I. Coexisting ovarian malignancy in young women with endometrial cancer. Obstet Gynecol. 2005 Oct; 106(4):693-9.
    View in: PubMed
    Score: 0.014
  8. John CS, Fong A, Alban R, Gillen J, Moore KM, Walsh CS, Li AJ, Rimel BJ, Amersi F, Cass I. Breast cancer surveillance following ovarian cancer in BRCA mutation carriers. Gynecol Oncol. 2022 01; 164(1):202-207.
    View in: PubMed
    Score: 0.011
  9. Liang MI, Wong DH, Walsh CS, Farias-Eisner R, Cohen JG. Cancer Genetic Counseling and Testing: Perspectives of Epithelial Ovarian Cancer Patients and Gynecologic Oncology Healthcare Providers. J Genet Couns. 2018 02; 27(1):177-186.
    View in: PubMed
    Score: 0.008
  10. Zakhour M, Danovitch Y, Lester J, Rimel BJ, Walsh CS, Li AJ, Karlan BY, Cass I. Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers. Gynecol Oncol. 2016 Nov; 143(2):231-235.
    View in: PubMed
    Score: 0.008
  11. Hodeib M, Cohen JG, Mehta S, Rimel BJ, Walsh CS, Li AJ, Karlan BY, Cass I. Recurrence and risk of progression to lower genital tract malignancy in women with high grade VAIN. Gynecol Oncol. 2016 06; 141(3):507-510.
    View in: PubMed
    Score: 0.007
  12. Mueller JJ, Holzapfel M, Han CH, Santos K, Gunderson C, Moore K, Erickson B, Leath CA, Diaz E, Walsh C, Wethington SL, Dejbakhsh SZ, Barakat RR, Gardner GJ, Hyman DM, Soslow RA, Leitao MM. Staging Lymphadenectomy in Patients With Clear Cell Carcinoma of the Ovary. Int J Gynecol Cancer. 2016 Jan; 26(1):120-4.
    View in: PubMed
    Score: 0.007
  13. Zakhour M, LaBrant L, Rimel BJ, Walsh CS, Li AJ, Karlan BY, Cass I. Too much, too late: Aggressive measures and the timing of end of life care discussions in women with gynecologic malignancies. Gynecol Oncol. 2015 Aug; 138(2):383-7.
    View in: PubMed
    Score: 0.007
  14. Cohen JG, Tran AQ, Rimel BJ, Cass I, Walsh CS, Karlan BY, Li AJ. Thrombocytosis at secondary cytoreduction for recurrent ovarian cancer predicts suboptimal resection and poor survival. Gynecol Oncol. 2014 Mar; 132(3):556-9.
    View in: PubMed
    Score: 0.006
  15. Zakhour M, Li AJ, Walsh CS, Cass I, Karlan BY, Rimel BJ. Post treatment surveillance of type II endometrial cancer patients. Gynecol Oncol. 2013 Dec; 131(3):609-12.
    View in: PubMed
    Score: 0.006
  16. Penner KR, Dorigo O, Aoyama C, Ostrzega N, Balzer BL, Rao J, Walsh CS, Cass I, Holschneider CH. Predictors of resolution of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma in premenopausal women treated with progestin therapy. Gynecol Oncol. 2012 Mar; 124(3):542-8.
    View in: PubMed
    Score: 0.006
  17. Fleming ND, Cass I, Walsh CS, Karlan BY, Li AJ. CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol Oncol. 2011 May 01; 121(2):249-52.
    View in: PubMed
    Score: 0.005
  18. Bull-Phelps SL, Garner EI, Walsh CS, Gehrig PA, Miller DS, Schorge JO. Fertility-sparing surgery in 101 women with adenocarcinoma in situ of the cervix. Gynecol Oncol. 2007 Nov; 107(2):316-9.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)